POSITIVE NOTES AND MOVEMENT OVER THE PAST FEW YEARSAugust...

POSITIVE NOTES AND MOVEMENT OVER THE PAST FEW YEARS

August 2009

Stirling Products Ltd says the company is well advanced in its plans to launch its natural botanical products in the US markets later this year and is hopeful of being able to have product on market there in time for the North American influenza season and the anticipated high rate of swine flu infection.


Stirling Products believes that ImmunoXel, acting as an immunomodulator, may prove to be just as effective as a preventative for the H1N1 influenza variant known as swine flu as it appears to be in seasonal flu prevention in the Ukraine, where it is widely used.

Stirling Products says it has 100 percent efficacy in treating drug-resistant tuberculosis patients with its natural product Immunoxel. Stirling says that a 12-patient trial in Kiev “confirmed a complete cure” of the seven extensively drug-resistant tuberculosis (XDR-TB) patients supplemented with the botanical immunotherapy product, Immunoxel which demonstrated 100 percent effectiveness and reduced treatment duration to under four months in all patients as opposed to the general 18-24 months of treatment with standard drugs

Stirling Journal On Herbal TB/HIV Remedy; Phosphagenics Cosmetics Deal With Metier Tribeca; Genera Passes TGA Audit; Aust Stem Cell centre 'Supports' Dr Livesey, Dr Traianedes; Avita's $5m Fortrend Draw-Down Facility
Stirling Products says a study published in ‘Future Medicine Immunotherapy’ shows “a high rate cure of [tuberculosis] patients co-infected with HIV treated with Immunoxel. Phosphagenics has an agreement with the New York-based Métier Tribeca to launch cosmetic products using its tocopheryl phosphate mixture or TPM.

Immunoxel has been shown to be safe and very effective in a variety of clinical conditions including but not limited to seasonal flu, influenza, acute respiratory infections, TB, hepatitis, HIV, autoimmune conditions, and malignancies.

Drug-resistant TB is on the rise throughout the world and is most frequently seen in the countries of the former Soviet Union, Asia, throughout the African continent and especially South Africa.

Conventional TB chemotherapy success rates are significantly lower in patients with Multi Drug Resistant (MDR) TB and Extensively Drug Resistant (XDR) TB. Recent US Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) surveys indicate that in the worst-affected countries, 10% of MDR-TB cases were XDR-TB. Current treatment of drug resistant TB can take up to 18-24 months. The disease is difficult and expensive to treat and outcomes are frequently poor. No significant new class of anti-TB drugs has been introduced in past 40 year! s and existing drugs are practically useless against advanced drugresistant TB.

Mr. Volodymyr Pylypchuk, Director of Ekomed the Company's Licensor, commented: "South Africa is burdened by one of the worst tuberculosis and HIV epidemics in the world. Our commercial partner Zodiac Capital has been working diligently and we are very excited to announce that that their effort paid off. Our Immunoxel works through completely novel immune mechanism and to the best of our knowledge is the only and most effective adjuvant to TB and AIDS drugs. The approach that we have developed drastically shortens treatment duration and can save countless lives right now. Our clinical studies conducted in Ukraine during last ten years have shown convincingly that we can offer reliable, cost-effective solutions to the global TB and HIV crisis."

Immunoxel is one of 26 phytopharmaceutical (botanical) products being commercialised globally under a Zodiac Capital Limited License Agreement that, subject to shareholder approval at a meeting s cheduled for 29 May 2009, the Company has agreed to joint venture with Zodiac Capital Limited as has previously been advised to the market.
.....................
.....................

Stirling Products Limited is engaged in the development and commercialisation of a range of metabolic modifiers that redirect energy from fat production to protein (meat), while improving the feed efficiency of animal production. Stirling is also developing therapeutic medications for heaves in horses and a treatment for obesity in companion ...

Activities: Commercialising patented beta agonist Repartitioning Feed Enhancers ('RFEs') for livestock, which are being positioned as replacement products and alternatives to the use of antibiotics and hormones as growth promoters.

In August last year STI completed a transaction acquiring worldwide licensing rights for the product PetQuench(tm)
PetQuench(tm) is fortified water that increases water consumption for dogs and cats. This is particularly useful for animals that are dehydrated or recovering from surgery, or as a simple aid to get pets to drink more water. Dogs and cats are becoming increasingly susceptible to urinary tract and kidney disorders in response to inadequate water consumption.

The company is projecting sales revenue of up to $3.5-5.0 million (Canadian) from its North American sales of this product over the next two years and intends to release the product in Australia by the end of the first quarter in 2009.

Australia has one of the highest incidences of pet ownership with over 63% of all households owning either a dog or a cat. Added to the increasing incidence of pet ownership in South East Asia, China and Japan, Stirling Animal Health is hoping to become an integral part of the $7 billion expenditure forecast on dog and cat foods and food related items.


"Since the announcement in August that we had acquired the rights to this product, we have been working hard to put the product back onto the market. I am pleased that we have to-date, met our deadlines for manufacture and offered some great deals for trade show attendees to reintroduce this product as a Stirling Animal initiative".


Stirling Products is developing patented animal growth agents that increase meat production, therefore improving the production efficiency of livestock animals, while decreasing fat accumulation for the benefit of consumers. The Stirling growth agents are under development for swine, poultry, cattle and sheep for global markets and are being positioned to take a major role in reducing the global use of antibiotics and steroid hormones in livestock. Stirling is also developing veterinary medications for heaves in horses through its joint venture in Europe (Pulmovet ApS, www.pulmovet.com) and an obesity treatment in companion animals.

Stirling Products recently acquired a Canadian company Progressive BioActives Incorporated (PBI) under its North American subsidiary, Stirling Products NA Inc. PBI is part of the Bioscience cluster established on located Prince Edward Island, Canada. PBI's lead product ProVale, is the latest high purity beta glucan extract that has been designed as an alternative tool for sustainable livestock management in face of increasing viral disease challenges where antibiotics have no or limited application. ProVale is available for targeted applications in swine, poultry and farmed aquaculture with a future focus on further developing applications for companion animals (e.g. horses, dogs, cats and reptiles).




May 2009...Australian healthcare company Stirling Products Limited (ASX:STI) is pleased to announce another milestone in the expansion of the licensed (pending joint venture approval) botanical products to markets outside of Ukraine. Immunoxel (Dzherelo) has been granted approval in South Africa. This approval will allow immediate sales of the phytoconcentrate as an immune adjuvant for TB and HIV treatment.



FURTHER INTERESTING READING FROM 2005.. $8.00?? I understand the world has changed drastically with the GFC and this company has suffered finacially however if they can hold on many of the key discussion and researched data points remains the same enjoy this link...

http://www.cohenresearch.com/reports/sti.ax_03-02-05.pdf

Maybe $8.00 is a little optimistic, but 1-2 dollars is acheivable in the long term (2-3 years)they just need to keep their heads above water and let us know what is going on every step of the way!



Disclaimer of course!